Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teva Pharmaceutical Industries Limited filings document material events, operating and financial results, capital-structure matters, governance, and shareholder voting for the Israel-based pharmaceutical issuer. Its 8-K reports include results announcements, conference-related outlook disclosures, and material definitive agreements, including amendments to a senior unsecured sustainability-linked revolving credit facility.
Teva's proxy materials cover annual meeting procedures, shareholder proposals, governance matters, and annual consolidated financial statements. The filing record also identifies the company's American Depositary Shares, each representing one ordinary share, as securities registered for trading under TEVA on the New York Stock Exchange.
Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.
These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.
Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.
A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.
Teva Pharmaceutical Industries President and CEO Richard D. Francis reported routine equity compensation activity involving restricted share units and related share sales. He exercised 13,043 restricted share units into ordinary shares and sold 6,153 ordinary shares at $34.35 per share to cover tax withholding obligations tied to the vesting. Following these transactions, he directly holds 1,183,682 ordinary shares and 39,130 restricted share units, with the sale executed under a pre-arranged Rule 10b5-1 trading plan.
TEVA notice reports a proposed resale of 13,043 ordinary shares tied to a restricted share unit award vesting on 06/05/2026. The filing also records a prior sale of 20,025 ordinary shares on 03/05/2026 for $634,159.71.
Teva Pharmaceutical Industries executive Matthew Shields exercised 16,195 restricted share units into ordinary shares and on the same day sold all 16,195 shares at an average price of $32.87. The sale, which also covered tax withholding obligations from vesting, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these transactions, Shields directly holds 9,989 ordinary shares.
Teva Pharmaceutical Industries Limited filed a Rule 144 notice reporting proposed sales of 16,195 Ordinary Shares. The filing lists the securities as resulting from a Restricted Share Unit award vesting with an execution date shown as 06/03/2026. The excerpt also records a prior sale of 17,295 shares on 03/05/2026 for $547,704.98.
Zaks Tal Zvi reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks received a grant of 7,242 restricted share units. The grant was made on May 28, 2026 as equity compensation, not as an open-market purchase.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The units vest on May 28, 2027. Following this grant, Zaks holds 7,242 restricted share units directly, each linked to an equal number of underlying ordinary shares, which may be represented by American Depositary Shares on a one-for-one basis.
Satchi-Fainaro Ronit reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director RSU grant: Director Ronit Satchi-Fainaro received 7,242 restricted share units as a compensation award. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one share. The award was granted on May 28, 2026 and will vest on May 28, 2027, subject to the plan’s conditions. Following this grant, the director holds 7,242 RSUs directly, and these may be settled in ordinary shares, which can be represented by American Depositary Shares on a 1:1 basis.
Nisen Perry reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries director Nisen Perry received a grant of 7,242 restricted share units. The award was granted on May 28, 2026 and will fully vest on May 28, 2027. Each restricted share unit gives a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share, which may be represented by American Depositary Shares.